Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. Cadavid D, Jurgensen S, Lee S PLoS One. 2013; 8(1):e53297. Epub 2013 Jan 04. PMID: 23308186. Abstract CommentRecommendBookmarkWatch